Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 5/20 | 0.36 |
| ▸ | BACE1 | P56817 | 6/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 3/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5007677 | 0.89 | UTS2R (0.37) | UTS2RBACE1CTSDGAA | |
| SCHEMBL8240547 | 0.83 | BACE1 (0.40) | NOS3BACE1CTSDTSHREGFR | |
| SCHEMBL4997151 | 0.82 | BACE1 (0.44) | UTS2RNOS3BACE1CTSDTSHR | |
| SCHEMBL8234440 | 0.79 | UTS2R (0.38) | UTS2RNOS3BACE1CTSDTSHR | |
| SCHEMBL8240648 | 0.76 | BACE1 (0.60) | BACE1CTSD | |
| Trifluoroacetic Acid SCHEMBL5007666 | 0.75 | BACE1 (0.36) | UTS2RBACE1CTSDGAA | |
| Trifluoroacetic Acid SCHEMBL5001837 | 0.74 | BACE1 (0.39) | BACE1CTSDNPSR1KDM4EHTT | |
| SCHEMBL14804299 | 0.72 | UTS2R (0.47) | UTS2RNPSR1GAA | |
| SCHEMBL2285635 | 0.71 | BACE1 (0.49) | BACE1CTSD | |
| SCHEMBL2285631 | 0.71 | BACE1 (0.49) | BACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293709-A1 | Novel 2-Amino-Heterocycles Useful in the Treatment of Abeta-Related Pathologies | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| US-20080293709-A1 | Novel 2-Amino-Heterocycles Useful in the Treatment of Abeta-Related Pathologies | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293709-A1 | Novel 2-Amino-Heterocycles Useful in the Treatment of Abeta-Related Pathologies | PSEN2, APP, PSEN1 | UTS2R 1765/4885NOS3 2189/4885BACE1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.